Cancer immunity最新文献

筛选
英文 中文
Hsp72 mediates stronger antigen-dependent non-classical MHC class Ib anti-tumor responses than hsc73 in Xenopus laevis. 在非洲爪蟾中,Hsp72介导比hsc73更强的抗原依赖性非经典MHC类Ib抗肿瘤反应。
Cancer immunity Pub Date : 2013-01-01 Epub Date: 2013-01-22
Hristina Nedelkovska, Jacques Robert
{"title":"Hsp72 mediates stronger antigen-dependent non-classical MHC class Ib anti-tumor responses than hsc73 in Xenopus laevis.","authors":"Hristina Nedelkovska,&nbsp;Jacques Robert","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The heat shock proteins (HSPs) gp96 and HSP70 mediate potent antigen-dependent anti-tumor T cell responses in both mammals and Xenopus laevis. We have shown that frogs immunized with total HSP70 generate CD8+ T cell responses against the Xenopus thymic lymphoid tumor 15/0 that expresses several non-classical MHC class Ib (class Ib) genes, but no classical MHC class Ia (class Ia). In the absence of class Ia, we hypothesized that hsp72 can prime class Ib-mediated anti-tumor unconventional CD8+ T cells in an antigen-dependent manner. To test this, we produced Xenopus recombinant HSP70 proteins (both the cognate hsc73 and the inducible hsp72) from stable 15/0 tumor transfectants. We used an in vivo cross-presentation assay to prime animals by adoptive transfer of HSP-pulsed antigen-presenting cells (APCs) and showed that both hsp72-and hsc73-Ag complexes have a similar potential to elicit class Ia-mediated T cell responses against minor histocompatibility (H) Ag skin grafts. In contrast, our in vivo cross-presentation assay revealed that hsp72 was more potent than hsc73 in generating protective immune responses against the class Ia-negative 15/0 tumors in an Ag-dependent and class Ib-mediated manner. These results suggest that hsp72 can stimulate class Ib-mediated immune responses and represents a promising candidate for immunotherapy against malignancies with downregulated class Ia expression.</p>","PeriodicalId":84394,"journal":{"name":"Cancer immunity","volume":"13 ","pages":"4"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3559192/pdf/130104.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31222718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CTLA-4 blockade in tumor models: an overview of preclinical and translational research. 肿瘤模型中的CTLA-4阻断:临床前和转化研究综述
Cancer immunity Pub Date : 2013-01-01 Epub Date: 2013-01-22
Joseph F Grosso, Maria N Jure-Kunkel
{"title":"CTLA-4 blockade in tumor models: an overview of preclinical and translational research.","authors":"Joseph F Grosso,&nbsp;Maria N Jure-Kunkel","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Cytotoxic T lymphocyte antigen-4 (CTLA-4) is a key negative regulator of T cell activation. A complex integration of positive and negative co-stimulatory signals in the well-defined B7:CD28/CTLA-4 pathway modulates the generation and maintenance of immune responses. Inhibiting negative regulation through binding of CTLA-4 has been shown to promote stimulation of adaptive immunity and potentiation of T cell activation. CTLA-4-blocking antibodies have demonstrated efficacy in various murine malignancy models when administered as monotherapy; additionally, they have shown synergistic anti-tumor activity when utilized with other agents, such as vaccines, chemotherapy, and radiation. Preclinical studies have supported the rationale for current clinical development of anti-CTLA-4 antibodies, including ipilimumab and tremelimumab, as novel therapeutic strategies to augment anti-tumor immunity in cancer. Both ipilimumab and tremelimumab have been evaluated extensively in melanoma; notably, ipilimumab was recently approved as monotherapy for the treatment of advanced melanoma. Tremelimumab is currently undergoing evaluation in phase II trials as monotherapy in melanoma and malignant mesothelioma, while ipilimumab is under clinical investigation in phase II and III trials in various tumor types, including in melanoma, prostate, and lung cancers as monotherapy and with other therapeutic modalities, such as chemotherapy and radiation. In this review, we will provide a detailed overview of preclinical advances that have delineated many features of CTLA-4 and have helped define its role in T cell response. We will also highlight clinical application of anti-CTLA-4 therapy in cancer and describe knowledge gaps that future studies may address.</p>","PeriodicalId":84394,"journal":{"name":"Cancer immunity","volume":"13 ","pages":"5"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3559193/pdf/130105.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31222719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy. 一种新的抗NY-ESO-1的人源性抗体提高了化疗的疗效。
Cancer immunity Pub Date : 2013-01-01 Epub Date: 2013-01-15
Anurag Gupta, Natko Nuber, Christoph Esslinger, Mareike Wittenbrink, Martin Treder, Alexandro Landshammer, Takuro Noguchi, Marcus Kelly, Sacha Gnjatic, Erika Ritter, Lotta von Boehmer, Hiroyoshi Nishikawa, Hiroshi Shiku, Lloyd Old, Gerd Ritter, Alexander Knuth, Maries van den Broek
{"title":"A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy.","authors":"Anurag Gupta,&nbsp;Natko Nuber,&nbsp;Christoph Esslinger,&nbsp;Mareike Wittenbrink,&nbsp;Martin Treder,&nbsp;Alexandro Landshammer,&nbsp;Takuro Noguchi,&nbsp;Marcus Kelly,&nbsp;Sacha Gnjatic,&nbsp;Erika Ritter,&nbsp;Lotta von Boehmer,&nbsp;Hiroyoshi Nishikawa,&nbsp;Hiroshi Shiku,&nbsp;Lloyd Old,&nbsp;Gerd Ritter,&nbsp;Alexander Knuth,&nbsp;Maries van den Broek","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We investigated whether antibodies against intracellular tumor-associated antigens support tumor-specific immunity when administered together with a treatment that destroys the tumor. We propose that released antigens form immune complexes with the antibodies, which are then efficiently taken up by dendritic cells. We cloned the first human monoclonal antibodies against the Cancer/Testis (CT) antigen, NY-ESO-1. We tested whether the monoclonal anti-NY-ESO-1 antibody (12D7) facilitates cross-presentation of a NY-ESO-1-derived epitope by dendritic cells to human CD8+ T cells, and whether this results in the maturation of dendritic cells in vitro. We investigated the efficacy of 12D7 in combination with chemotherapy using BALB/c mice bearing syngeneic CT26 tumors that express intracellular NY-ESO-1. Human dendritic cells that were incubated with NY-ESO-1:12D7 immune complexes efficiently stimulated NY-ESO-1(157-165)/HLA-A2-specific human CD8+ T cells to produce interferon-γ, whereas NY-ESO-1 alone did not. Furthermore, the incubation of dendritic cells with NY-ESO-1:12D7 immune complexes resulted in the maturation of dendritic cells. Treatment of BALB/c mice that bear CT26/NY-ESO-1 tumors with 5-fluorouracil (5-FU) plus 12D7 was significantly more effective than chemotherapy alone. We propose systemic injection of monoclonal antibodies (mAbs) against tumor-associated antigens plus a treatment that promotes the local release of those antigens resulting in immune complex formation as a novel therapeutic modality for cancer.</p>","PeriodicalId":84394,"journal":{"name":"Cancer immunity","volume":"13 ","pages":"3"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3559191/pdf/130103.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31222717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma. 转移性黑色素瘤患者ny - eso -1特异性免疫压力和逃逸。
Cancer immunity Pub Date : 2013-01-01 DOI: 10.5167/UZH-79657
L. von Boehmer, Muriel Mattle, P. Bode, Alexandro Landshammer, C. Schäfer, N. Nuber, G. Ritter, L. Old, H. Moch, N. Schäfer, E. Jäger, A. Knuth, M. van den Broek
{"title":"NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma.","authors":"L. von Boehmer, Muriel Mattle, P. Bode, Alexandro Landshammer, C. Schäfer, N. Nuber, G. Ritter, L. Old, H. Moch, N. Schäfer, E. Jäger, A. Knuth, M. van den Broek","doi":"10.5167/UZH-79657","DOIUrl":"https://doi.org/10.5167/UZH-79657","url":null,"abstract":"During cancer progression, malignant cells may evade immunosurveillance. However, evidence for immunological escape in humans is scarce. We report here the clinical course of a melanoma patient whose initial tumor was positive for the antigens NY-ESO-1, MAGE-C1, and Melan-A. Upon immunization with a recombinant vaccinia/fowlpox NY-ESO-1 construct, the patient experienced a mixed clinical response and spreading of the NY-ESO-1 epitopes in the CD4+ T cell compartment. After NY-ESO-1 protein + CpG immunization, the patient's anti-NY-ESO-1 IgG response increased. Over the following years, progressing lesions were resected and found to be NY-ESO-1-negative while being positive for MAGE-C1, Melan-A, and MHC-I. The fatal, inoperable brain metastasis was analyzed after his death and also proved to be NY-ESO-1-negative, while being positive for MAGE-C1 and Melan-A, as well as MHC-I. We propose that cancer control and cancer escape in this patient were governed by NY-ESO-1-specific immunological pressure. Our findings provide evidence for the existence of immunoediting and immunoescape in this cancer patient.","PeriodicalId":84394,"journal":{"name":"Cancer immunity","volume":"13 1","pages":"12"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70661992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 34
Intraepithelial T cells and tumor-associated macrophages in ovarian cancer patients. 卵巢癌患者上皮内T细胞和肿瘤相关巨噬细胞的研究。
Cancer immunity Pub Date : 2013-01-01 Epub Date: 2013-01-15
Paulette Mhawech-Fauceglia, Dan Wang, Liaquat Ali, Shashikant Lele, Michael A Huba, Song Liu, Kunle Odunsi
{"title":"Intraepithelial T cells and tumor-associated macrophages in ovarian cancer patients.","authors":"Paulette Mhawech-Fauceglia,&nbsp;Dan Wang,&nbsp;Liaquat Ali,&nbsp;Shashikant Lele,&nbsp;Michael A Huba,&nbsp;Song Liu,&nbsp;Kunle Odunsi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The aims of this study were to evaluate the prognostic significance of tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs) in patients with familial ovarian cancer. Clinical and pathological information were retrieved from the Gilda Radner Familial Ovarian Cancer Registry (GRFOCR) in Buffalo, NY. Immunohistochemistry was performed on paraffin-embedded tissue specimens of GRFOCR participants using specific antibodies for CD3+, CD8+, CD25+, FOXP3+, CD68+, and CD163+. The correlation between the frequencies of TILs and TAMs and clinic-pathologic parameters were determined. Overall survival was determined using univariate and multivariate Cox proportional hazards models. High tumor grade correlated with higher frequencies of CD3+ (p = 0.019), CD68+ (p = 0.025), CD163+ (p = 0.018), and T(reg) (CD25+ FOXP3+) (p = 0.024) cells. Higher stage correlated with higher frequencies of CD163+ cells (p = 0.012). There were correlations between the frequencies of CD68+ and CD3+ (p = 0.029), between T(reg) and each of CD3+ (p = 0.002), CD8+ (p = 0.018), and CD68+ (p = 0.028) cells. In univariate analysis, age and T(reg) significantly predicted patient survival. In multivariate survival analysis, T(reg) frequency was the only significant predictor of prognosis in patients with familial ovarian cancer [HR = 0.92; 95% CI 0.87 - 0.98; p = 0.012]. We concluded that interaction between TILs and TAMs in familial EOC also exists, and tumors with high T(reg) frequencies have a more favorable outcome. Thus, therapeutic strategies to modulate tumor T(reg) infiltration could be beneficial for patients with familial ovarian cancer.</p>","PeriodicalId":84394,"journal":{"name":"Cancer immunity","volume":"13 ","pages":"1"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3559189/pdf/130101.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31221148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy. 一种新的抗NY-ESO-1的人源性抗体提高了化疗的疗效。
Cancer immunity Pub Date : 2013-01-01 DOI: 10.5167/UZH-81963
Anurag Gupta, N. Nuber, C. Esslinger, Mareike Wittenbrink, M. Treder, Alexandro Landshammer, T. Noguchi, M. Kelly, S. Gnjatic, E. Ritter, L. von Boehmer, H. Nishikawa, H. Shiku, L. Old, G. Ritter, A. Knuth, M. van den Broek
{"title":"A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy.","authors":"Anurag Gupta, N. Nuber, C. Esslinger, Mareike Wittenbrink, M. Treder, Alexandro Landshammer, T. Noguchi, M. Kelly, S. Gnjatic, E. Ritter, L. von Boehmer, H. Nishikawa, H. Shiku, L. Old, G. Ritter, A. Knuth, M. van den Broek","doi":"10.5167/UZH-81963","DOIUrl":"https://doi.org/10.5167/UZH-81963","url":null,"abstract":"We investigated whether antibodies against intracellular tumor-associated antigens support tumor-specific immunity when administered together with a treatment that destroys the tumor. We propose that released antigens form immune complexes with the antibodies, which are then efficiently taken up by dendritic cells. We cloned the first human monoclonal antibodies against the Cancer/Testis (CT) antigen, NY-ESO-1. We tested whether the monoclonal anti-NY-ESO-1 antibody (12D7) facilitates cross-presentation of a NY-ESO-1-derived epitope by dendritic cells to human CD8+ T cells, and whether this results in the maturation of dendritic cells in vitro. We investigated the efficacy of 12D7 in combination with chemotherapy using BALB/c mice bearing syngeneic CT26 tumors that express intracellular NY-ESO-1. Human dendritic cells that were incubated with NY-ESO-1:12D7 immune complexes efficiently stimulated NY-ESO-1(157-165)/HLA-A2-specific human CD8+ T cells to produce interferon-γ, whereas NY-ESO-1 alone did not. Furthermore, the incubation of dendritic cells with NY-ESO-1:12D7 immune complexes resulted in the maturation of dendritic cells. Treatment of BALB/c mice that bear CT26/NY-ESO-1 tumors with 5-fluorouracil (5-FU) plus 12D7 was significantly more effective than chemotherapy alone. We propose systemic injection of monoclonal antibodies (mAbs) against tumor-associated antigens plus a treatment that promotes the local release of those antigens resulting in immune complex formation as a novel therapeutic modality for cancer.","PeriodicalId":84394,"journal":{"name":"Cancer immunity","volume":"13 1","pages":"3"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70662365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 21
Mechanism of dichotomy between CD8+ responses elicited by apoptotic and necrotic cells. 凋亡细胞和坏死细胞诱导CD8+反应分化的机制。
Cancer immunity Pub Date : 2013-01-01 Epub Date: 2013-01-15
Matthew R Buckwalter, Pramod K Srivastava
{"title":"Mechanism of dichotomy between CD8+ responses elicited by apoptotic and necrotic cells.","authors":"Matthew R Buckwalter,&nbsp;Pramod K Srivastava","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Apoptotic cells are significantly more immunogenic than necrotic cells, even though both forms are identical in antigenic content. When a combination of apoptotic and necrotic cells are used to immunize, the phenotype conferred by apoptotic cells, i.e., high immunogenicity, is dominant. However, necrotic cells are not immunosuppressive or tolerogenic. Apoptotic and necrotic cells are taken up by antigen-presenting cells in an equivalent manner. The priming of naïve T cell response is also equivalent. However, the CD8+ T cells elicited by apoptotic cells expand, accumulate, and express effector function, while those primed by the necrotic cells do not. This dichotomy does not extend to CD4+ cells. Apoptotic and necrotic cells elicit equivalent CD4+ T cell priming, accumulation, and function. The deficit in CD8+ T cell function elicited by necrotic cells can be overcome to varying degrees by anti-CD40 antibody and ligands for TLR4 and TLR9; conversely, the immunogenicity of apoptotic cells can be abrogated by blocking anti-CD154 antibody. Our results indicate that immunization with apoptotic cells leads to engagement of CD40 on antigen-presenting cells; this is essential for their ability to elicit mature functional CD8+ cells. The necrotic cells fail to engage CD40, and this failure is the basis of their lack of immunogenicity. These differences have consequences for the understanding of mechanisms of cross-presentation and for efforts toward immunotherapy of cancers and autoimmune pathologies.</p>","PeriodicalId":84394,"journal":{"name":"Cancer immunity","volume":"13 ","pages":"2"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3559190/pdf/130102.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31221149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer. BORIS/CTCFL mRNA异构体在上皮性卵巢癌中的表达及表观遗传调控
Cancer immunity Pub Date : 2013-01-01 Epub Date: 2013-01-22
Petra A Link, Wa Zhang, Kunle Odunsi, Adam R Karpf
{"title":"BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer.","authors":"Petra A Link,&nbsp;Wa Zhang,&nbsp;Kunle Odunsi,&nbsp;Adam R Karpf","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Cancer germline (CG) genes are normally expressed in germ cells and aberrantly expressed in a variety of cancers; their immunogenicity has led to the widespread development of cancer vaccines targeting these antigens. BORIS/CTCFL is an autosomal CG antigen and promising cancer vaccine target. BORIS is the only known paralog of CTCF, a gene intimately involved in genomic imprinting, chromatin insulation, and nuclear regulation. We have previously shown that BORIS is expressed in epithelial ovarian cancer (EOC) and that its expression coincides with promoter and global DNA hypomethylation. Recently, 23 different BORIS mRNA variants have been described, and have been functionally grouped into six BORIS isoform families (sf1-sf6). In the present study, we have characterized the expression of BORIS isoform families in normal ovary (NO) and EOC, the latter of which were selected to include two groups with widely varying global DNA methylation status. We find selective expression of BORIS isoform families in NO, which becomes altered in EOC, primarily by the activation of BORIS sf1 in EOC. When comparing EOC samples based on methylation status, we find that BORIS sf1 and sf2 isoform families are selectively activated in globally hypomethylated tumors. In contrast, CTCF is downregulated in EOC, and the ratio of BORIS sf1, sf2, and sf6 isoform families as a function of CTCF is elevated in hypomethylated tumors. Finally, the expression of all BORIS isoform families was induced to varying extents by epigenetic modulatory drugs in EOC cell lines, particularly when DNMT and HDAC inhibitors were used in combination.</p>","PeriodicalId":84394,"journal":{"name":"Cancer immunity","volume":"13 ","pages":"6"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3559194/pdf/130106.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31222720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The genealogy of SEREX. SEREX的家谱。
Cancer immunity Pub Date : 2012-01-01 Epub Date: 2012-05-01
Michael Pfreundschuh
{"title":"The genealogy of SEREX.","authors":"Michael Pfreundschuh","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":84394,"journal":{"name":"Cancer immunity","volume":"12 ","pages":"7"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380345/pdf/cim-120107.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30838331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The journey from autologous typing to SEREX, NY-ESO-1, and cancer/testis antigens. 从自体分型到SEREX、NY-ESO-1和癌症/睾丸抗原的历程。
Cancer immunity Pub Date : 2012-01-01 Epub Date: 2012-05-01
Yao-Tseng Chen
{"title":"The journey from autologous typing to SEREX, NY-ESO-1, and cancer/testis antigens.","authors":"Yao-Tseng Chen","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":84394,"journal":{"name":"Cancer immunity","volume":"12 ","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380346/pdf/cim-120108.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30838332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书